I can see Novartis interested in this.Sales of Lucentis fell 25% last year, losing ground to Eylea. Buying OPT and using in combination with Lucentis is a no brainer. Novartis MC is USD 220B.
Ann: Security Class Reinstatement to Quotation- OPTOB, page-121
-
- There are more pages in this discussion • 197 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
89.5¢ |
Change
-0.015(1.65%) |
Mkt cap ! $1.101B | |||
| Open | High | Low | Value | Volume |
| 91.0¢ | 92.0¢ | 87.5¢ | $1.496M | 1.676M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1705 | 89.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 90.5¢ | 46363 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| OPT (ASX) Chart |